The global adrenocortical carcinoma drugs market at a CAGR of over 6% during the forecast period

Tuesday, August 6, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Global Adrenocortical Carcinoma Drugs Market: About this market Adrenocortical carcinoma drugs significantly include chemotherapeutics. This adrenocortical carcinoma drugs market analysis considers sales from chemotherapy and targeted therapy segments. Our analysis also considers the sales of adrenocortical carcinoma drugs

Asia, Europe, North America, and ROW. In 2018, the chemotherapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as increased survival rate and effectivity will significantly help the chemotherapy segment in maintaining its leading market position. Also, our global adrenocortical carcinoma drugs report has observed market growth factors such as increasing prevalence of genetic disorders leading to adrenocortical carcinoma, regulatory incentives, and advantages of novel drugs over chemotherapeutics. However, lack of effective therapies, lack of preclinical models for testing novel therapeutics, and side-effects of drugs may hamper the growth of the adrenocortical carcinoma drugs industry over the forecast period. Download the full report: Global Adrenocortical Carcinoma Drugs Market: Overview Advantages of novel drugs over chemotherapeutics Novel therapies have minimal side effects and longer survival rate compared with chemotherapeutics. As a result, the development and approval of novel therapies are increasing, augmenting the sales of vendors. These factors will lead to the expansion of the global adrenocortical carcinoma drugs market at a CAGR of over 6% during the forecast period. Advances in imaging techniques for adrenal tumors Advances in imaging techniques are facilitating enhanced diagnostic accuracy for adrenocortical carcinoma in a non-invasive manner. This is assisting healthcare professionals in treating patients effectively by administering appropriate therapeutics and drugs. As a result, the sales of adrenocortical carcinoma drugs will increase. Therefore, this trend will have a positive impact on the overall market growth. Competitive Landscape With the presence of a few major players, the global adrenocortical carcinoma drugs market is concentrated. This robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading Adrenocortical carcinoma drugs manufacturers, which include Bristol-Myers Squibb Co., Eli Lilly and Co., Laboratoire HRA Pharma SAS, Progenics Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. Also, the adrenocortical carcinoma drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.Download the full report: About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email: Tel: +1 (718) 213 4904 Website:

Cision View original content:

SOURCE ReportBuyer

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store